Results 31 to 40 of about 13,054 (213)

HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?

Cancers, 2022
Histone deacetylases (HDACs) are a group of enzymes that modify gene expression through the lysine acetylation of both histone and non-histone proteins, leading to a broad range of effects on various biological pathways. New insights on this topic broadened the knowledge on their biological activity and even more questions arose from those discoveries.
Squarzoni, Angelica, Scuteri, Arianna, Cavaletti, Guido   +2 more
openaire   +2 more sources

Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors

Frontiers in Immunology, 2022
Host defense peptides (HDPs) are an integral part of the innate immune system acting as the first line of defense. Modulation of HDP synthesis has emerged as a promising host-directed approach to fight against infections.
Melanie A. Whitmore, Hong Li, Hong Li, Wentao Lyu, Wentao Lyu, Sharmily Khanam, Sharmily Khanam, Guolong Zhang   +7 more
doaj   +1 more source

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy

Frontiers in Cell and Developmental Biology, 2020
Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy.
Bin Tu, Bin Tu, Meng Zhang, Tuanbing Liu, Yongzhuo Huang, Yongzhuo Huang, Yongzhuo Huang   +6 more
doaj   +1 more source

Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression

Acta Pharmaceutica Sinica B, 2019
Artemisinin and its derivatives (ARTs) were reported to display heme-dependent antitumor activity. On the other hand, histone deacetylase inhibitors (HDACi) were known to be able to promote heme synthesis in erythroid cells.
Cai-Ping Chen, Kun Chen, Zhiqi Feng, Xiaoan Wen, Hongbin Sun   +4 more
doaj   +1 more source

HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. [PDF]

PLoS ONE, 2011
Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase which promotes cell proliferation and survival, is abnormally overexpressed in numerous tumors of epithelial origin, including colorectal cancer (CRC).
Chia-Wei Chou, Ming-Shiang Wu, Wei-Chien Huang, Ching-Chow Chen   +3 more
doaj   +1 more source

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights [PDF]

Pharmacology & Therapeutics, 2014
Initially regarded as "epigenetic modifiers" acting predominantly through chromatin remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase or simply deacetylase inhibitors, have since been recognized to exert multiple cytotoxic actions in cancer cells, often through acetylation of non-histone proteins.
Prithviraj, Bose, Yun, Dai, Steven, Grant   +2 more
openaire   +2 more sources

HDACi facilitated DHA-induced apoptosis. A.

, 2013
Combination treatment with HDACi and DHA increased cell death. Cells were treated with 4 mM NaB, 1.25 μM SAHA, 10 μM DHA or combination of NaB/SAHA and DHA for 24 h. Cell viabilities were measured by MTT assay. B.
Paul B. S. Lai (317945), George Gong Chen (115651), Jingping Yun (111732), Lili Liu (111724), Chris Zhiyi Zhang (111721), Yun Cao (111731), Yinghua Pan (111727)   +6 more
core   +1 more source

Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population

Cancer Management and Research, 2020
Feili Chen,1 Diwen Pang,1 Hanguo Guo,1 Xinmiao Jiang,1 Sichu Liu,1 Ling Huang,1 Xiaojuan Wei,1 Zhanli Liang,1 Xiaoxia Wang,2 Wenyu Li1 1Lymphoma Division, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of ...
Chen F, Pang D, Guo H, Jiang X, Liu S, Huang L, Wei X, Liang Z, Wang X, Li W   +9 more
doaj  

Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma

Frontiers in Oncology, 2022
BackgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Radiotherapy (RT) controls HCC unsatisfactorily and temporarily.
Yu-Fan Liu, Yu-Fan Liu, Yun Chiang, Yun Chiang, Feng-Ming Hsu, Feng-Ming Hsu, Chiao-Ling Tsai, Chiao-Ling Tsai, Jason Chia-Hsien Cheng, Jason Chia-Hsien Cheng, Jason Chia-Hsien Cheng   +10 more
doaj   +1 more source

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Biologics: Targets and Therapy, 2013
Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addition to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter
Ververis, K, Hiong, A, Karagiannis, TC, Licciardi, PV   +3 more
openaire   +6 more sources